文献速递核素与放射性配体治疗肿瘤 PET/CT

转移性去势抵抗性前列腺癌患者中177Lu-PSMA分子放疗延长灵活给药方案的随机2期试验(FLEX-MRT):研究方案

Randomized Phase 2 Trial of an Extended and Flexible Dosing Schedule of 177Lu-PSMA Molecular Radiotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT): Study Protocol.
PubMed 文献 · J Nucl Med · 2025-10-01

FLEX-MRT是一项研究者发起的前瞻性2期、平行组、随机、对照、开放标签、单中心试验,计划1:1随机90例mCRPC患者,比较延长灵活给药方案(最多12周期,允许治疗假期)与标准固定方案(最多6周期,每6周一次)的2年生存率。

要点

  • FLEX-MRT试验旨在比较延长灵活给药与标准固定给药方案177Lu-PSMA-617治疗的2年生存率。
  • 计划随机90例mCRPC患者,1:1分配至对照组45例和研究组45例。
  • 研究组最多12周期并根据反应设置治疗假期,对照组按标准固定方案最多6周期每6周一次。

核心结论

  • 该研究方案旨在确定延长灵活给药方案较标准固定方案(最多6周期每6周一次)能否改善mCRPC患者的2年生存率。

研究设计与样本

  • FLEX-MRT为研究者发起的前瞻性2期、平行组、随机、对照、开放标签、单中心试验。
  • 计划中央随机90例mCRPC患者,按1:1比例分配至2个治疗组。
  • 对照组45例接受已批准的标准固定给药方案;研究组45例接受最多12周期并根据反应设置治疗假期的延长灵活方案。
  • 主要入组标准为符合Pluvicto治疗条件者(既往接受雄激素受体信号抑制剂、既往化疗、符合PSMA PET VISION标准)。
  • 关键排除标准为既往接受过177Lu-PSMA-617治疗及末次骨髓抑制治疗不足6周者。

主要发现

  • 主要终点为2年生存率,生存时间自首次177Lu-PSMA-617治疗周期日期计算。
  • 次要终点包括按常见不良事件术语标准评价的安全性、剂量学以及总生存期和无进展生存期。
  • 反应评估基于每周期SPECT/CT及治疗假期期间每12周PSMA PET/CT。
  • 无进展生存期的进展定义为影像学、前列腺特异性抗原水平或临床进展,或任何原因死亡。

关键数值与推荐

  • 标准固定给药方案为每6周一次、最多共6次剂量。
  • 研究组给药最多12周期,并可根据反应设置治疗假期。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

[177Lu]Lu-PSMA-617 radiopharmaceutical therapy has been approved for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) using a fixed dosing schedule of once every 6 wk for up to a total of 6 doses. We hypothesized that patients may benefit from a flexible and extended dosing schedule, up to 12 doses with potential "treatment holiday" periods. Objective: The objective of this study is to determine the 2-y survival rate of patients with mCRPC treated with an extended and flexible dosing schedule of [177Lu]Lu-PSMA-617 therapy in comparison to patients treated with the standard fixed dosing schedule of a maximum of 6 treatment cycles once every 6 wk. Study Design: The FLEX-MRT trial is an investigator-initiated prospective phase 2, parallel group, randomized, controlled, open-label, single-center trial in men with mCRPC to determine the efficacy of a flexible and extended dosing schedule of [177Lu]Lu-PSMA-617 therapy. Key inclusion criteria are patients eligible for Pluvicto (i.e., prior androgen receptor signaling inhibitors, prior chemotherapy, PSMA PET VISION criteria). Key exclusion criteria are prior [177Lu]Lu-PSMA-617 therapy and less than 6 wk since last myelosuppressive therapy. The trial aims to centrally randomize 90 patients in a 1:1 ratio to 2 treatment arms. In the control arm, patients will be treated with the approved standard dosing schedule (n = 45). In the investigational arm, patients will be treated with up to 12 cycles and with potential treatment holidays depending on response (n = 45). Response assessment is based on SPECT/CT at each cycle and on PSMA PET/CT during treatment holiday periods (every 12 wk). Primary endpoint is the 2-y survival rate. Survival is calculated from the date of the first cycle of [177Lu]Lu-PSMA-617 therapy. Secondary endpoints include safety by Common Terminology Criteria for Adverse Events and dosimetry and determination of overall and progression-free survival (evidence of progression as defined by radiographic, prostate-specific antigen level, or clinical progression, or death from any cause).

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Holzgreve A, Delker A, Ells Z, et al. Randomized Phase 2 Trial of an Extended and Flexible Dosing Schedule of 177Lu-PSMA Molecular Radiotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT): Study Protocol. J Nucl Med. 2025. PMID: 40876952. doi:10.2967/jnumed.125.269495

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。